Table 2.

ORR, PFS, and OS in the entire patient cohort in patients with different characteristics

Patients	No. of patients	≥VGPR (%)*	ORR (%)*	Median PFS (mo)	Median OS (mo)
All patients	79	35.4	60.8	9.7	25.6
FISH high-risk	30	36.7	53.0	9.3	22.8
FISH standard-risk	39	35.9	67.0	11.1	N/R
Pretreatment with bortezomib	50	28.0	56.0	8.6	25.6
None	29	48.3	69.0	12.4	N/R
1 line	42	28.6	54.8	8.6	25.6
2-3 lines	8	25.0	62.5	4.4	9.8
Pretreatment with lenalidomide	42	26.2	55.0	8.3	20.6
None	37	45.9	67.6	12.3	N/R
1 line	33	33.3	57.6	8.5	21.6
2-3 lines	9	0.0	44.4	5.4	13.5
Pretreatment with lenalidomide and bortezomib	32	18.8	46.9	7.1	17.4
Pretreatment with neither lenalidomide nor bortezomib	19	47.4	63.2	12.0	N/R
No. of prior treatment lines
1-2	50	42.0	66.0	12.0	N/R
3-6	29	24.1	51.7	7.8	19.9
Relapse status at start of BBD
Relapsing to the preceding treatment line*	58	36.2	63.8	11.1	27.3
Refractory to the preceding treatment line*	21	28.6	52.4	8.0	23.7

N/R, not reached.

^*Last line before start of BBD.

^**Differences between groups not significant.